Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
@article{Briones2006ExenatideAG, title={Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus}, author={Ma Briones and Mandeep Bajaj}, journal={Expert Opinion on Pharmacotherapy}, year={2006}, volume={7}, pages={1055 - 1064} }
Exenatide is a glucagon-like peptide 1 receptor agonist, which has recently received FDA approval in the US for the treatment of Type 2 diabetes. Exenatide is an incretin mimetic that improves glycaemic control in patients with diabetes through acute mechanisms, such as glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion and slowing of gastric emptying, as well as chronic mechanisms that include enhancement of β-cell mass in rodent studies and…
59 Citations
In-Silico Design of Novel Glucagon-Like Peptide 1 Mutants as Candidate for New Peptide Agonist Drugs
- Medicine, Biology
- 2021
The GLP-1 protein performs critical functions in the body such as: stimulating the insulin secretion from the pancreatic β-cells, stimulating the biosynthesis of insulin and insulin sensitivity, increasing the β-cell proliferation and apoptosis protection, inhibiting the glucagon secretion, gastric emptying, and food intake.
DPP-4 Inhibition and the Path to Clinical Proof
- MedicineFront. Endocrinol.
- 2019
This article summarizes the development of the DPP-4 inhibition concept from its early stages in the 1990s, and underscores that the development has its basis in scientific studies on pathophysiology of type 2 diabetes and the importance of targeting the islet dysfunction.
The role of incretin on diabetes mellitus.
- Medicine, BiologyActa medica Indonesiana
- 2009
The attempt to increase both incretin hormones - in this case by using GLP-1 agonist and DPP-IV inhibitor - is one of treatment modalities to control the glucose blood level, either as a monotherapy or a combination therapy.
A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo
- Biology, MedicinePeptides
- 2011
Novel Modified GLP-1 Derivatives with Prolonged Glucose-Lowering Ability In Vivo
- Biology, ChemistryInternational Journal of Peptide Research and Therapeutics
- 2019
Chemical coupling of GLP-1 analog to HSA is innovatively achieved by solid-phase peptide synthesis in this study and shows prolonged glucose-lowering ability in vivo and demonstrates that the albumin-conjugated GLP (7–37)(Ala8Aib)-Cys-HSA mimics the function of native GLp-1 with prolonged activity.
A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes.
- Biology, MedicineDrug discovery today. Disease mechanisms
- 2013
Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus
- Medicine, BiologyClinical Drug Investigation
- 2017
rE- 4 twice a day has a pharmacokinetic profile similar to exenatide and rE-4 with metformin after single and multiple doses in Chinese patients with T2DM, and could improve glycemic control effectively.
Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
- Biology, ChemistryJournal of medicinal chemistry
- 2013
13c is a promising long-lasting GLP-1 mimetic that may be suitable for clinical use following further research, and a once daily administration to db/db mice for 7 weeks provided long-term beneficial effects by lowering glycated hemoglobin levels to 5.05%, lower than with liraglutide treatment.
New Drugs for Type 2 Diabetes Mellitus
- Medicine, BiologyDrugs
- 2012
Several new drugs with glucose-lowering efficacy that may offer certain advantages have recently become available in some countries that offer new options for treating type 2 diabetes, and Beneficial or neutral effects on bodyweight are an attractive feature of the new drugs.
References
SHOWING 1-10 OF 89 REFERENCES
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
- Biology, MedicineRegulatory Peptides
- 2004
Enhancing incretin action for the treatment of type 2 diabetes.
- Medicine, BiologyDiabetes care
- 2003
The need for daily injections of potentially immunogenic GLP-1-derived peptides and the potential for unanticipated side effects with chronic use of DPP-IV inhibitors will require ongoing scrutiny of the risk-benefit ratio for these new therapies as they are evaluated in the clinic.
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
- Medicine, BiologyAmerican journal of physiology. Endocrinology and metabolism
- 2003
The data suggest that, even with this short duration of therapy, exendin-4 treatment had a significant effect on glucose homeostasis.
The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.
- MedicineThe Journal of clinical endocrinology and metabolism
- 2002
It is concluded that exendin-4 is a potent and long-lasting insulinotropic agent in nondiabetic and diabetic subjects.
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
- MedicineThe Journal of clinical endocrinology and metabolism
- 2003
In conclusion, AC2993 acutely and markedly reduces fasting and postprandial glucose concentrations in patients with type 2 diabetes.
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
- MedicineDiabetes care
- 2003
AC2993 had significant effects on HbA(1c) levels in patients not currently achieving optimal glucose control with diet and/or OAAs, confirming AC2993 effects on fasting and postprandial glycemia.
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
- Medicine, BiologyDiabetes/metabolism research and reviews
- 2002
Continuous subcutaneous administration of the GLP‐1‐based therapy of type 2 diabetes mellitus for six weeks in patients with rather advanced disease greatly improved glucose profiles and lowered body weight, haemoglobin A1C, and free fatty acids.
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
- MedicineAmerican journal of physiology. Regulatory, integrative and comparative physiology
- 1999
A marked effect of GLP-1 on appetite is demonstrated by showing enhanced satiety and reduced energy intake in patients with diabetes type 2.
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
- Medicine, BiologyThe New England journal of medicine
- 1992
GLIP has an antidiabetogenic effect, and it may therefore be useful in the treatment of patients with NIDDM, indicating that GLIP had an insulinotropic effect.
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
- MedicineAmerican journal of physiology. Endocrinology and metabolism
- 2001
The results are in accord with the possibility that exendin-4 may be a potential treatment for type 2 diabetes, particularly for obese patients, because it acts to reduce plasma glucose at least partly by a delay in gastric emptying, as well as by reducing calorie intake.